Document is current
Any future updates will be listed below
-
Authors
Sukhtankar, Devki D.
Cardarelli, Pina M.
Jalilizeinali, Bita
Setia, Gayatri
Kim, GaYeon
Chang, Li-wen
Tsai, Cheng-yuan
Caculitan, Niña G.
Schuster, Michael W.
- License Information
-
More Information
Article History
Received: 27 August 2025
Accepted: 20 January 2026
First Online: 4 February 2026
Declarations
:
: Burixafor was previously being developed by TaiGen Biotechnology Col Ltd. This work was supported by GPCR Therapeutics, Inc. and Exicure, Inc. DS, PC and NC are employees of GPCR Therapeutics USA, a subsidiary of Exicure, Inc. GK is a former employee of GPCR Therapeutics, Inc. LC and CT are employees of TaiGen Biotechnology Col Ltd and own company stock. Medical writing support was provided by Guissou Dabiri, PhD of GD Scientific & Medical Writing, LLC and was funded by GPCR Therapeutics, Inc.
: Financial Disclosure Statement: Burixafor was previously being developed by TaiGen Biotechnology Col Ltd. This work was supported by GPCR Therapeutics, Inc. and Exicure, Inc. DS, PC and NC are employees of GPCR Therapeutics USA, a subsidiary of Exicure, Inc. GK is a former employee of GPCR Therapeutics, Inc. LC and CT are employees of TaiGen Biotechnology Col Ltd and own company stock. Medical writing support was provided by Guissou Dabiri, PhD of GD Scientific & Medical Writing, LLC and was funded by GPCR Therapeutics, Inc.
